Shi-jun Y. Yue

Shijiazhuang, CN 
Shijiazhuang, CN 
OverviewLocationsClinical Research

Overview

Shi-jun Yue practices in Shijiazhuang, China. Their top areas of expertise are Diarrhea, Muscle Atrophy, Indigestion, and COVID-19.

Their clinical research consists of co-authoring 87 peer reviewed articles. MediFind looks at clinical research from the past 15 years.

Locations

Shijiazhuang, China
Other Locations
Key Laboratory Of Shaanxi Administration Of Traditional Chinese Medicine For TCM Compatibility, And State Key Laboratory Of Research And Development Of Characteristic Qin Medicine Resources, And Shaanxi Key Laboratory Of Chinese Medicine Fundamentals And New Drugs Research, Xi'an, 712046, China
Key Laboratory Of Shaanxi Administration Of Traditional Chinese Medicine For TCM Compatibility, Hebei, 050200, China
Chuzhou, 239012, China
Zhenjiang, 212400, China
Key Laboratory Of Shaanxi Administration Of Traditional Chinese Medicine For TCM Compatibility, And State Key Laboratory Of Research & Development Of Characteristic Qin Medicine Resources, And Shaanxi Key Laboratory Of Chinese Medicine Fundamentals And New Drugs Research, China
Nanjing, 210023, China
Key Laboratory Of Marine Drugs, Qingdao, 266003, China
Beijing Key Laboratory Of Bio Characteristic Profiling For Evaluation Of Rational Drug Use, Beijing, 100038, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

87 Total Publications

RETRACTED: Yue et al. A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways. Molecules 2019, 24, 2165.
RETRACTED: Yue et al. A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways. Molecules 2019, 24, 2165.
Journal: Molecules (Basel, Switzerland)
Published: April 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yue's expertise for a condition
ConditionClose
        View All 9 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile